Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 8;16(12):e75314.
doi: 10.7759/cureus.75314. eCollection 2024 Dec.

Risk Factors Associated With the Development of Calciphylaxis in Patients With Chronic Kidney Disease: A Systematic Review

Affiliations
Review

Risk Factors Associated With the Development of Calciphylaxis in Patients With Chronic Kidney Disease: A Systematic Review

Cyprian O Ogah et al. Cureus. .

Abstract

Calciphylaxis is a rare but potentially life-threatening disease that is not yet completely understood. It occurs mainly in patients with chronic kidney disease termed calcific uremic arteriolopathy (CUA) but also affects patients with normal renal function. Although this disease's pathogenesis is unclear, it is associated with the dysregulation of calcium and phosphate and subsequent calcification of peripheral arterioles. Calciphylaxis has up to 80% mortality, even with multidisciplinary and multimodal treatment modalities. The available literature identified some relevant risk factors associated with the development of calciphylaxis, but the authors differ significantly in risk profiling. Moreover, most papers on calciphylaxis are observational studies, namely case series, case reports, cohort, and cross-sectional studies. Although recently available articles mentioned some risk factors, the studies mainly focused on diagnosis, treatment, and prognosis with limited emphasis on structured risk profiling. In addition, experimental and systemic review studies on risk factors associated with calciphylaxis are lacking. Thus, this systematic review's primary focus is to determine risk factors associated with developing calciphylaxis in patients with chronic kidney disease. We searched electronic databases from 2018 to 2024 for articles that contained relevant risk factors linked with the development of calciphylaxis using the keywords calciphylaxis, chronic kidney disease, and risk factors. We identified 486 articles, removed duplicate papers from selected articles, applied inclusion and exclusion criteria, and conducted a quality assessment test. Two independent authors performed data extraction manually, and we compared the results for consistency and accuracy. Twenty-two articles met the eligibility criteria, but only 16 articles passed the quality assessment appraisal and were included in the systematic review. We identified 1,739 patients: 664 (38.2%) and 1075 (61.81%) were males and females, respectively. A total of 1373 (78.95%) were on dialysis, and 926 (53.25%) were diabetics. Caucasians and patients with obesity were 695 (37.90%) and 613 (35.25%), respectively. At the time of diagnosis, 599 (34.45%), 311 (17.90%), and 278 (15.99%) were on vitamin K antagonists (VKA), vitamin D, and calcium phosphate binders. The number of patients with elevated parathyroid hormone was 196 (11.27%). Our study found no experimental or systematic reviews that primarily focused on risk factors associated with the development of calciphylaxis. Our research indicated that dialysis is the most frequent risk factor linked to the development of calciphylaxis. Other risk factors include being caucasian, female gender, obese, diabetic mellitus (DM), having elevated parathyroid hormone, and use of VKA (warfarin), vitamin D, and calcium phosphate binders. These findings are consistent with the evidence seen in most of the articles we reviewed. However, the papers we studied are mainly observational mono-centered research articles, with the majority having a small sample size. Thus, we recommend a multicenter, large-scale experimental study to assess risk factors and profiling for the development of calciphylaxis in patients with chronic kidney disease.

Keywords: calcific uremic arteriolopathy (cua); calciphylaxis; chronic kidney disease; chronic renal failure; dialysis; dm; end stage renal disease; pth; risk factors; vka.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. A PRISMA flow chart for studies selection.
PRISMA: Preferred Reporting Items for Systematic Review and Meta-Analysis
Figure 2
Figure 2. A graphic representation of the most common risk factors associated with the development of calciphylaxis in patients with chronic kidney disease.
DM: diabetes mellitus; VKA: vitamin K antagonist; PTH: parathyroid hormone; Ca++: calcium NB: The numbers on the graph are in percentages.
Figure 3
Figure 3. The figure represents the distribution of males and females in each of the reviewed articles.
The numerical numbers inside each square bracket along the X-axis represent the articles studied.

Similar articles

References

    1. Multimodality approach to treat calciphylaxis in end-stage kidney disease patients. Lajoie C, Ghanemi A, Bourbeau K, Sidibé A, Wang YP, Desmeules S, Mac-Way F. Ren Fail. 2023;45:2256413. - PMC - PubMed
    1. The Australian Calciphylaxis Registry: reporting clinical features and outcomes of patients with calciphylaxis. Ruderman I, Toussaint ND, Hawley CM, Krishnasamy R, Pedagogos E, Lioufas N, Elder GJ. Nephrol Dial Transplant. 2021;36:649–656. - PubMed
    1. The multifactorial pathogenesis of calciphylaxis: a case report. Turek M, Stępniewska J, Różański J. Am J Case Rep. 2021;22:0. - PMC - PubMed
    1. Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study. Gaisne R, Péré M, Menoyo V, Hourmant M, Larmet-Burgeot D. BMC Nephrol. 2020;21:63. - PMC - PubMed
    1. Calciphylaxis episodes in the Australia and New Zealand Dialysis and Transplant Registry. Toussaint ND, Davies CE, Bongetti E, et al. Kidney Int Rep. 2024;9:951–959. - PMC - PubMed

LinkOut - more resources